In a significant move to streamline its R&D operations, Novonesis, a global leader in biosolutions, has selected Benchling as its digital platform to enhance the discovery, development, and testing processes across its scientific teams. Serving more than four billion people daily and operating in 30 industries, Novonesis delivers solutions that boost fuel efficiency, improve crop resilience, and enrich infant nutrition. With the recent merger of Novozymes and Chr. Hansen, Benchling’s platform is being rolled out to 1,500 scientists at Novonesis to manage the increasing scale and complexity of enzyme and microbial research.

Positioned at the forefront of the fast-growing biosolutions industry, Novonesis draws from a robust biological toolbox, combining expertise in enzyme and microbial technologies with advanced ingredient systems for food, nutrition, pharmaceuticals, and agriculture. The merger has significantly expanded the company, adding 40 R&D centers, 20 production sites, and a global workforce of 10,000 employees. By implementing a unified digital data model through Benchling, Novonesis aims to integrate these global teams and speed up innovation.

"Our R&D ambitions at Novonesis have never been higher, and a robust digital strategy is essential to meet those goals," said Martin S. Borchert, Senior Director of Scientific Data Strategy and Systems at Novonesis. "Extending our partnership with Benchling allows us to work at unprecedented speed and scale. We’re automating key R&D processes and building a strong foundation for cutting-edge data tools. With AI-ready data and integrated systems, we can start applying machine learning to our work right now."

A cornerstone of this transformation is a shared data model designed to ensure that every piece of information generated during the R&D lifecycle—from early research stages to product launch—is both easily accessible and usable. Novonesis scientists can quickly convert proprietary data into actionable analytics, leading to more confident decision-making. Benchling's platform eliminates data bottlenecks, improves quality across the board, and empowers high-throughput teams to accelerate innovation.

"Novonesis is a shining example of how biological innovation is driving the creation of sustainable, safer products that we depend on — from circular plastics and plant-based proteins to carbon capture processes," said Sajith Wickramasekara, CEO and co-founder of Benchling. "We're thrilled to support their team in advancing faster, smarter, and more connected R&D."

Benchling's platform is designed to be adaptable, enabling Novonesis to enforce FAIR data standards (findable, accessible, interoperable, and reusable) while maintaining the flexibility needed to model diverse use cases across different teams. As Novonesis continues to grow and collaborate with internal and external partners, Benchling ensures that regulatory compliance and data security are maintained through controlled access and auditing features.